SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

被引：0

作者：

Polverelli, N.

Elli, E.

Abruzzese, E.

Palumbo, G. A.

Benevolo, G.

Breccia, M.

Tiribelli, M.

Bonifacio, M.

Tieghi, A.

Martino, B.

Sgherza, N.

D'Adda, M.

Bergamaschi, M.

Crugnola, M.

Cavazzini, F.

Bosi, C.

Binotto, G.

Isidori, A.

Bartoletti, D.

Auteri, G.

Latagliata, R.

Gandolfi, L.

Scaffidi, L.

Cattaneo, D.

Codeluppi, K.

Trawinska, M.

Griguolo, D.

Cuneo, A.

Krampera, M.

Semenzato, G.

Di Raimondo, F.

Lemoli, R. M.

Cavo, M.

Vianelli, N.

Russo, D.

Iurlo, A.

Palandri, F.

机构：

[1] Univ Brescia, ASST Spedali Civili Brescia, Dept Clin & Expt Sci, Unit Blood Dis & Stem Cells Transplantat, Brescia, Italy

[2] ASST Monza, San Gerardo Hosp, Div Hematol, Monza, Italy

[3] Osped S Eugenio, Div Hematol, Rome, Italy

[4] Univ Catania, Dept Sci Med Chirurg & Tecnol Avanzate GF Ingrass, Catania, Italy

[5] Citta Salute & Sci Hosp, Div Hematol, Turin, Italy

[6] Univ Sapienza, Div Cellular Biotechnol & Hematol, Rome, Italy

[7] Azienda Sanit Univ Integrata Udine, Div Hematol & BMT, Udine, Italy

[8] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[9] Azienda USL IRCCS Reggio Emilia, Dept Hematol, Reggio Emilia, Italy

[10] Azienda Osped Bianchi Melacrino Morelli, Div Hematol, Reggio Di Calabria, Italy

[11] Casa Sollievo Sofferenza, Div Hematol, San Giovanni Rotondo, Italy

[12] ASST Spedali Civili Brescia, Div Hematol, Brescia, Italy

[13] IRCCS AOU San Martino IST, Dept Internal Med DiMI, Clin Hematol, Genoa, Italy

[14] Azienda Osped Univ Parma, Div Hematol, Parma, Italy

[15] Univ Ferrara, Div Hematol, Ferrara, Italy

[16] AUSL Piacenza, Div Hematol, Piacenza, Italy

[17] Univ Padua, Unit Hematol & Clin Immunol, Padua, Italy

[18] Marche Nord Hosp, Hematol & Stem Cell Transplant Ctr, Pesaro, Italy

[19] St Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy

[20] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Hematol, Milan, Italy

来源：

HAEMATOLOGICA | 2019年 / 104卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

B005

引用

页码：3 / 3

页数：1

共 50 条

[1] Second primary malignancy in myelofibrosis patients treated with ruxolitinib
Polverelli, Nicola
Elli, Elena M.
Abruzzese, Elisabetta
Palumbo, Giuseppe A.
Benevolo, Giulia
Tiribelli, Mario
Bonifacio, Massimiliano
Tieghi, Alessia
Caocci, Giovanni
D'Adda, Mariella
Bergamaschi, Micaela
Binotto, Gianni
Heidel, Florian H.
Cavazzini, Francesco
Crugnola, Monica
Pugliese, Novella
Bosi, Costanza
Isidori, Alessandro
Bartoletti, Daniela
Auteri, Giuseppe
Latagliata, Roberto
Gandolfi, Lisa
Martino, Bruno
Scaffidi, Luigi
Cattaneo, Daniele
D'Amore, Fabio
Trawinska, Malgorzata M.
Stella, Rossella
Markovic, Uros
Catani, Lucia
Pane, Fabrizio
Cuneo, Antonio
Krampera, Mauro
Semenzato, Gianpietro
Lemoli, Roberto M.
Vianelli, Nicola
Breccia, Massimo
Russo, Domenico
Cavo, Michele
Iurlo, Alessandra
Palandri, Francesca
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 356 - 368
[2] Refractory primary autoimmune myelofibrosis treated with ruxolitinib
Otoukesh, Salman
Song, Joo Y.
Mojtahedzadeh, Mona
Mokhtari, Sally
Marcucci, Guido
Pullarkat, Vinod
Ali, Haris
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) : E283 - E285
[3] Second primary malignancies in patients receiving treatment with ruxolitinib for myelofibrosis - a regional experience
Schofield, J.
Wells, R.
Nicholson, T.
Butt, N. M.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 77 - 77
[4] Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study
Joshi, Utsav
Bhattarai, Adheesh
Gaire, Suman
Gill, Simrat
Agrawal, Vishakha
Yadav, Sumeet Kumar
Low, Soon Khai
Dhakal, Prajwal
Bhatt, Vijaya Raj
Kouides, Peter A.
LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3456 - 3461
[5] Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib
Zhou, Amy
Kong, Tim
Fowles, Jared S.
Jung, Chun-Ling
Allen, Maggie J.
Fisher, Daniel A. C.
Fulbright, Mary
Nemeth, Elizabeta
Ganz, Tomas
Oh, Stephen T.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (04) : E49 - E52
[6] Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib
Zarzour, Ahmad
Tabarroki, Ali
Taftaf, Rokana
Visconte, Valeria
Ai, Jing
Hamilton, Betty K.
Papadantonakis, Nikolaos
Lichtin, Alan E.
Horwitz, Leonard J.
Advani, Anjali S.
Sekeres, Mikkael A.
Tiu, Ramon V.
BLOOD, 2014, 124 (21)
[7] Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
Maffioli, Margherita
Giorgino, Toni
Mora, Barbara
Iurlo, Alessandra
Elli, Elena
Finazzi, Maria Chiara
Caramella, Marianna
Rumi, Elisa
Carraro, Maria Cristina
Polverelli, Nicola
D'Adda, Mariella
Malato, Simona
Rossi, Marianna
Molteni, Alfredo
Vismara, Alessandro
Sissa, Cinzia
Spina, Francesco
Anghilieri, Michela
Cattaneo, Daniele
Renso, Rossella
Bellini, Marta
Pioltelli, Maria Luisa
Cavalloni, Chiara
Barraco, Daniela
Accetta, Raffaella
Bertu, Lorenza
Della Porta, Matteo Giovanni
Passamonti, Francesco
BLOOD ADVANCES, 2019, 3 (21) : 3196 - 3200
[8] Risk of second primary malignancy in patients with primary myelofibrosis: A SEER database study.
Joshi, Utsav
Bhattarai, Adheesh
Gaire, Suman
Gill, Simrat
Agrawal, Vishakha
Bhetuwal, Uttam
Kouides, Peter
Bhatt, Vijaya Raj
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Ruxolitinib for the treatment of primary myelofibrosis
Swaim, Starla J.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (06) : 453 - 462
[10] Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib
Gerds, Aaron T.
Tauchi, Tetsuzo
Ritchie, Ellen
Deininger, Michael
Jamieson, Catriona
Mesa, Ruben
Heaney, Mark
Komatsu, Norio
Minami, Hironobu
Su, Yun
Shaik, Naveed
Zhang, Xiaoxi
DiRienzo, Christine
Zeremski, Mirjana
Chan, Geoffrey
Talpaz, Moshe
LEUKEMIA RESEARCH, 2019, 79 : 38 - 44

← 1 2 3 4 5 →